Core Points - DXS International plc announced that all resolutions at the Annual General Meeting (AGM) were passed successfully [2][3] - The CEO, David Immelman, provided an update on the company's progress during the AGM [3] Voting Results - Resolution 1: 14,681,963 votes for (100.00%), 0 votes against [3] - Resolution 2: 14,647,713 votes for (99.77%), 34,250 votes against (0.23%) [3] - Resolution 3: 14,671,963 votes for (99.97%), 5,000 votes against (0.03%) [3] - Resolution 4: 14,671,963 votes for (99.97%), 5,000 votes against (0.03%) [3] - Resolution 5: 14,676,963 votes for (99.97%), 5,000 votes against (0.03%) [3] - Resolution 6: 14,671,963 votes for (99.97%), 5,000 votes against (0.03%) [3] Company Overview - DXS International provides healthcare information and digital clinical decision support systems, aiming to improve healthcare outcomes and contribute to NHS efficiency savings [4]

Financial Reporting Schedule - Digitalist Group Plc will publish its Financial Statement bulletin for the period 1 January - 31 December 2025 on Friday, 27 February 2026 [1] - The Financial Statements for 2025 will be available on the company's website on Friday, 27 March 2026 [1] - The Business Review for Q1-Q3 2026 will be published on Friday, 24 April 2026, with the Half-year report for H1 2026 on Friday, 28 August 2026, and the Business Review for Q1-Q3 2026 on Friday, 30 October 2026 [2] Annual General Meeting - Digitalist Group Plc's Annual General Meeting is scheduled for Tuesday, 28 April 2026 [2] - Financial Statements will be published in both Finnish and English and will be accessible on the group's website immediately after publication [2]

Core Viewpoint - Hargreave Hale AIM VCT plc reported its financial results for the year ending September 30, 2025, highlighting a marginal loss in NAV and share price total returns, while also announcing a proposed final dividend and a special dividend for shareholders [2][5][22]. Financial Highlights - The net asset value (NAV) per share decreased to 36.46 pence from 40.55 pence, resulting in a NAV total return of -0.22% for the year [6][16]. - The market capitalization fell from £142.34 million to £127.41 million, with the share price dropping from 39.00 pence to 34.40 pence, reflecting a share price total return of -1.54% [6][18]. - Dividends paid per share remained constant at 4.00 pence, with a final dividend of 1 penny proposed and a special dividend of 2 pence approved by the Board [5][21][22]. Investment Activity - The Company invested £4.8 million in seven qualifying companies during the year, with 98.98% of its VCT tax value invested in qualifying investments as of September 30, 2025 [7][19]. - The fair value of qualifying investments was reported at £73.0 million, representing 54.1% of NAV, while non-qualifying investments included £8.4 million in equities and £21.1 million in short-dated investment-grade corporate bonds [19]. Market Context - The Investment Association reported sustained outflows from UK equities for four consecutive years, with fiscal policy changes negatively impacting sectors like leisure and hospitality [9]. - The London Stock Exchange experienced a thirty-year low for initial public offerings, prompting the Company to become more active in private capital markets [11]. Performance Overview - The Company reported a marginal loss across the year, but noted a positive return of +9.36% in the second half of the financial year, marking the first period of improved performance after four years of decline [13]. - The earnings per share total return was a loss of -0.14 pence, with revenue income decreasing by 14% to £2.5 million due to reduced allocations to high-yielding non-qualifying equity investments [17]. Shareholder Engagement - The Company is committed to maintaining shareholder engagement, providing updates and opportunities for interaction through its website and planned events [50][55]. - Shareholders are encouraged to participate in the upcoming AGM scheduled for February 5, 2026, where key resolutions will be proposed [49]. Future Outlook - The Company anticipates a positive impact from upcoming legislative changes that will increase thresholds for VCT capital deployment, although concerns remain regarding reduced income tax relief for investors [69][70]. - The Investment Manager reported an improvement in deal flow post-period end, with £2.9 million invested across two qualifying investments [71].

ST HELIER, Jersey, Dec. 19, 2025 (GLOBE NEWSWIRE) -- On December 1, 2025 Caledonia Mining Corporation Plc (“Caledonia” or “the Company”) (NYSE AMERICAN, AIM and VFEX: CMCL) issued an announcement regarding proposed changes to the royalty and tax regimes, as they apply to gold miners, in the Republic of Zimbabwe’s 2026 National Budget. The proposed changes related inter alia to royalties and tax deductibility of capital expenditure. Caledonia notes that, on December 17, 2025, the Zimbabwe Minister of Finance ...

Transparency LawDisclosure in accordance with the Law of 2 May 2007 Pursuant to Articles 15 §1 and 18 §1 of the Law of 2 May 2007 on the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market, NV Bekaert SA (“Bekaert”) publishes the following information: Status as of 15 December 2025 Basic data Total capital: € 159 782 000.00 Total number of securities conferring voting rights: 51 315 868 shares Total number of voting rights (the denominator): 51 315 868 (one vot ...

Core Viewpoint - Hepsor AS and AS Phoenix Land have established a joint venture to develop the next phase of the Manufaktuuri quarter in Tallinn, focusing on residential and commercial real estate development [1][2][4]. Group 1: Joint Venture Details - The new joint venture, Hepsor PHX5 OÜ, is equally owned by Hepsor AS and AS Phoenix Land, with a non-monetary contribution of EUR 5.8 million from AS Phoenix Land [2]. - The joint venture will initiate the development of the property located at Manufaktuuri 3, which has a valid detailed plan [3]. Group 2: Development Plans - An architectural competition is planned to determine the best design solution for the high-rise building, which can be up to 60 storeys tall [3]. - The Manufaktuuri quarter is expected to include approximately 1,100 homes and commercial premises in the future [6]. Group 3: Previous Developments - This project marks the fifth development in the Manufaktuuri quarter, with previous projects having completed 421 homes, 97% of which have been sold [5]. - Ongoing projects include the first phase of the Manufaktuuri Vabrik project, which will add 152 new homes, and the M12 development project, which will complete 49 new homes [5]. Group 4: Company Background - Hepsor AS is a developer of residential and commercial real estate operating in Estonia, Latvia, and Canada, with a portfolio of 25 development projects totaling 178,200 m² [6]. - The company has created 2,003 homes and nearly 44,787 m² of commercial space over fourteen years, implementing innovative engineering solutions for energy efficiency [6].

Core Viewpoint - Sampo plc has initiated a share buyback program with a maximum value of EUR 150 million, which commenced on November 6, 2025, and has executed significant buybacks on December 18, 2025, acquiring a total of 244,940 shares at an average price of EUR 10.19 per share [1][2]. Group 1: Share Buyback Details - On December 18, 2025, Sampo plc acquired a total of 244,940 A shares across various markets, with the following daily volumes and average prices: - 4,512 shares at EUR 10.17 on AQEU - 103,883 shares at EUR 10.19 on CEUX - 26,668 shares at EUR 10.18 on TQEX - 109,877 shares at EUR 10.19 on XHEL [1]. - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and was authorized by Sampo's Annual General Meeting on April 23, 2025 [1]. Group 2: Ownership Post-Buyback - Following the transactions, Sampo plc now holds a total of 7,667,191 A shares, which represents 0.29% of the total number of shares in the company [2].

Core Insights - Vallourec and Geostock have signed a Memorandum of Understanding to enhance collaboration in developing infrastructure for the energy transition, focusing on hydrogen and carbon capture, utilization, and storage (CCUS) [1][5][6] Group 1: Partnership Details - The collaboration emphasizes hydrogen storage, leveraging Vallourec's Delphy storage system, which can store up to 100 tons of hydrogen, and Geostock's mined lined rock caverns, suitable for capacities exceeding 500 tons [2][4] - Both companies will share expertise in well architecture and tubular solutions for hydrogen and CCUS applications, enhancing the safety and performance of underground storage infrastructures [4][6] Group 2: Strategic Importance - This partnership is part of Vallourec's strategy to collaborate with key players in the New Energies sector, addressing industrial, environmental, and economic challenges of the energy transition [5][6] - Geostock aims to broaden its range of solutions for underground hydrogen storage, leveraging Vallourec's expertise in metallic materials across various storage techniques [6][9]

Core Points - Danish Aerospace Company A/S is changing its Certified Advisor due to the termination of collaboration with Baker Tilly Corporate Finance [1][2] - HC Andersen Capital has been appointed as the new Certified Advisor, effective January 1, 2026 [2] Company Overview - Danish Aerospace Company A/S operates in advanced medical instrumentation and engineering fields, primarily focused on space applications [3][4] - The company specializes in developing, integrating, and applying medical technologies for space, with products benefiting both space research and terrestrial applications [3][4] - Danish Aerospace Company has developed various equipment for spaceflight, including respiratory equipment and bicycle ergometers for astronauts [4][5] - The company's quality system is certified to BS EN ISO 9001:2015 and BS EN 9100:2018, which are recognized standards in the industry [5]

Core Insights - IBA has acquired ORA, a leader in radiochemistry, enhancing its position in the nuclear medicine sector [1][2] - The acquisition aims to integrate IBA's cyclotron technology with ORA's advanced solutions, providing competitive offerings for hospitals and radiopharmacy networks [3] - This move aligns with IBA's strategic initiatives in nuclear medicine, including partnerships for isotope production and innovation in patient care [4] Financial Aspects - The acquisition is valued between €15-20 million on a cash-free, debt-free basis and is expected to be immediately accretive to IBA's revenue and EBITDA [5] - The transaction will be financed through IBA's own funds and existing credit facilities, with no material impact on IBA's 2025 financial guidance [5] Company Profiles - IBA is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, and radiopharmaceuticals, employing approximately 2,100 people [7] - ORA Group is recognized for its automated PET radiopharmaceutical synthesizers, contributing to the production of sterile injectable PET drug products [8]